natgillin/translations-raw huggingface dataset:
First and second circuit section 1a, 1b each comprise a selection stage 2a, 2b for receiving input signals (INPUTS) generated in known manner and relating to the status of a portion of a railway line (e.g. 
Prva 1 druga sekcija komunikacijskih krugova la 1 1b svaka sadrži podsklop odabira 2a, 2b za prijam ulaznih signala (INPUTS) generiranih na poznati način koji se odnose na stanje dijela željezničke pruge (npr.
a second BCH encoder configured to BCH-encode PLP data to generate an error protected data; 
drugi BHC uređaj za kodiranje (301) podešen za BHC-kodiranje PLP podataka za stvaranje podataka zaštićenih od pogreške;
The method of claim 1, wherein the carbohydrate is present in an amount sufficient to have stability comparable to that of a lyophilized composition comprising sucrose, 0.01% polysorbate-20, pH 6.0, 50 mM Citrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da ona ima stabilnost koja odgovara onoj za liofiliziranu kompoziciju koja sadrži saharozu, 0,01 % polisorbata-20, pH 6,0, 50 mM citrata.
a microwave generator; a microwave-transparent window for transmission of microwave radiation from the microwave generator into the vacuum chamber; 
(c) mikrovalno-transparentni prozor (54) za prijenos mikrovalnog zračenja od mikrovalnog generatora (56) u vakuumsku komoru (22);
A pharmaceutical composition comprising a salt of a compound according to any of the claims 1 to 9 together with customary pharmaceutical diluents, excipients and/or carriers. 
Farmaceutski pripravak, naznačen time što sadrži sol spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 9, kao i uobičajene farmaceutske razrjeđivače, pomoćne tvari 1/ili podloge.
The compound according to claim 1, wherein the compound is vortioxetine (L)-pyroglutamate or vortioxetine (D)-pyroglutamate in crystalline form with XRPD reflections at 10.72, 12.14, 16.22 and 18.59 (°2θ) (±0.1 °2θ). 
Spoj prema patentnom zahtjevu 1, naznačen time što je vortioksetin (L)-piroglutamat ili vortioksetin (D)- piroglutamat u kristalnom obliku s XRPD refleksijama kod 10,72, 12,14, 16,22 1 18,59 (220) (+0,1 220).
The compound of claim 1, wherein the compound has formula IV 
Spoj sukladno zahtjevu 1, pri čemu spoj ima formulu IV čiš
Magnesium stearate was screened into the blender and the mixing process continued for a further 1 minute at 17 rpm. 
Magnezij stearat se prosije u miješalicu i postupak miješanja nastavi daljnju 1 minutu pri 17 okr/min.
A pharmaceutical composition made by mixing a compound of claim 22 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji se dobiva miješanjem spoja prema bilo kojim zahtjevima 1 do 13 i farmaceutski prihvatljivog nosača.
said polymeric composition being characterized in that: 
spomenuta polimerna kompozicija koja je okarakterizirana time da:
changing the transmission parameters based on the analysis of step E) in order to increase the quality of the transmitted audio signal. 
F) promjene parametara prijenosa na osnovi analize u koraku E) kako bi se povećalo kvalitetu prenesenog audio signala.
Soft or slightly heated butter is added, using a wooden spatula. 
Drvenom kuhačom dodati omekšani ili blago zagrijani maslac.
A method of modifying a boat so as to enable remote control of the boat, the boat having a manually operated control device having an output connected to an electronic control, characterized by: connecting an output of a receiver to said electronic control, the receiver being adapted to receive wireless signals from a hand-held transmitter, wherein the connecting step is performed without disturbing a connection between the manually operated control device and the electronic control, wherein a signal generated by the receiver acts in parallel with a signal from said manually operated control device. 
Metoda modifikacije plovila kojom se omogućava daljinsko upravljanje plovilom, plovilo ima manualnu upravljačku kontrolu koja ima izlaz spojen tako da upravlja elektroničkom upravljačkom kontrolom, naznačen time da se izlaz prijemnika spaja na istu elektroničku kontrolu koja se može upravljati sa spomenutom ručnom upravljačkom kontrolom, prijemnik je prilagođen tako da prima bežične signale sa ručnog odašiljača, pri čemu je postupak spajanja izveden tako da ne poremeti spoj između manualne i elektroničke upravljačke kontrole, pri čemu signal kojeg šalje odašiljač djeluje paralelno signalu sa spomenute ručne kontrole.
According to a further subject matter or a further embodiment of the present invention, provision is made for the filter element to be elastic and to be arranged and/or attached, at least in its edge region, in the region of the capsule base. 
Kapsula s porcijom (1) prema jednom od prethodnih zahtjeva, naznačena time da je element filtera (7) elastičan i smješten je, barem u njegovom rubnom području (7'), u području osnovice kapsule (3).
The method of claim 2, wherein pressure in said catalyst trough and said supercritical trough are identical, and temperature in said catalyst trough and said supercritical trough are also identical. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što tlakovi u navedenom katalizatorskom koritu i navedenom superkritičnom koritu su isti, a i temperature u navedenom katalizatorskom koritu i navedenom superkritičnom koritu su također iste.
and wherein the antibody or fragment comprises a variable heavy chain (VH) in which CDR2 comprises or consists of the amino acid sequence of: 
Xaje Vili LL pri čemu protutijelo ili fragment sadrži varijabilni teški lanac (VH) u kojem CDRI sadrži ili se sastoji od sekvence amino kiselina:
An immunoconjugate comprising an antibody or antigen-binding fragment thereof covalently attached to a cytotoxic agent, wherein the antibody is a monoclonal antibody that binds to CD22 and (i) comprises a full-length heavy chain having the amino acid sequence of SEQ ID NO:88, and a full-length light chain having the amino acid sequence of SEQ ID NO:87; or (ii) is a full-length antibody in which the heavy chains have the amino acid sequence of SEQ ID NO:88, and the light chains have the amino acid sequence of SEQ ID NO:87. 
Imunokonjugat, naznačen time, da obuhvaća monoklonsko protutijelo ili njegov fragment koji se veže na CD22 i kovalentno je priključen na citotoksično sredstvo, pri čemu protutijelo sadrži varijabilnu domenu jakog lanca, koja ima aminokiselinsku sekvencu od SEQ ID NO: 16 i varijabilnu domenu slabog lanca, koja ima aminokiselinsku sekvencu od SEQ ID NO: 18.
An in vitro method for therapy follow-up in patients being suspected of having sepsis wherein the concentration of mature adrenomedullin (ADM) (1-52-amide) and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that are selected from the group comprising an anti-adrenomedullin antibody and an anti-ADM antibody fragment binding to ADM and that bind to two different regions within the region of mature adrenomedullin (21-52-amide) and/ or adrenomedullin-Gly, that is amino acid 21-52-amide (SEQ ID No. 
HR P20170427 T1 PATENTNI ZAHTJEVI Postupak postterapijske kontrole in vitro kod pacijenata za koje se sumnja da imaju sepsu, naznačen time se koncentraciju zrelog adrenomeđulina (ADM) (amid 1-52) i/ili zreli ADM 1-52-Gly u uzorku tjelesne tekućine iz navedenog pacijenta sa sepsom se određuje uz pomoć testa koji sadrži dva liganda koje se bira iz skupine koju čine protutijelo protiv adrenomedulina i fragment protutijela protiv ADM koji se veže na ADM, te koji se vežu na dva različita područja unutar područja zrelog adrenomedulina (2amid 1-52) i/ili adrenomedulin-Gly, koji je amid slijeda aminokiselina 21-52 (SEQ ID No.
The invention also comprises an antibody or antibody fragment which competes for a binding epitope on human PD-1 with any of the antibodies described above, and which blocks the binding of human PD-L1 or human PD-L2 to human PD-1 with an IC50 of about 1 nM or lower. 
1/s ili sporije; veže se za humani PD-1 sa kaieoC od oko 3 x 10% Vs ili sporije; ili blokira vezanje humanog PD-L1 i/ili humanog PD-L2 za humani PD-1 sa ICso od oko 1 nM ili niže.
Kit comprising five RNAs, each encoding a different antigen selected from: 
Komplet koji sadrži pet RNK, koje svaka kodiraju različiti antigen koji je odabran od:
Example 1.1: Quantification of the amount of insoluble particles 
Datum podnošenja europske prijave patenta:
optionally substituted heterocyclyl; 
opcijski supstituiran heterociklil;
The antibody of claim 7, wherein at least 20% to 100% of the N-linked oligosaccharides in the Fc region are bisected. 
Protutijelo u skladu s patentnim zahtjevom 7, naznačeno time, da su najmanje 20% do 100% N-vezanih oligosaharida u Fc regiji prepolovljeni.
parts of the resin thus obtained were dissolved in 33 parts of water. 
66 dijelova tako dobijene smole otopimo u 33 dijela vode.
A cloning or expression vector comprising one or more DNA sequences according to claim 8. 
Vektor kloniranja ili ekspresije, naznačen time da sadrži jednu ili više DNA sekvenci prema zahtjevu 13.
having an antibody-dependent cell-mediated phagocytosis (ADCP) activity; and 
(b) da ima aktivnost stanično-posredovane fagocitoze zavisne od antitijela (ADCP);
The pharmaceutical composition of claim 2, characterized in that the total weight of the drug impurities is not more than 0.5 percent of the weight of the compound imiquimod. 
Farmaceutski pripravak iz patentnog zahtjeva 2, naznačen time, da ukupna težina nečistoća u lijeku nije veća od 0,5 posto težinskog udjela spoja imikvimoda.
recovering said antibodies, or one of their functional divalent fragment or derivatives from the culture medium or said cultured cells. 
izolaciju rečenih antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met iz medija za kulturu ili rečenih kultiviranih stanica.
A compound according to [1], a salt thereof or a hydrate of the foregoing, wherein R1 represents a group represented by the formula —NR11aR11b, wherein R11a and R11b represent the same meaning as recited in [1]. 
Spoj prema zahtjevu 1, njegova sol ili hidrat navedenog, naznačen time da R' predstavlja skupinu prikazanu sa formulom -NR/'*R'", pri čemu R''*i R!" imaju isto značenje kako je navedeno u zahtjevu 1.
The method of claim 1, wherein the amount of the acylating agent ranges from about 1 to about 15, from about 1 to about 10 or from about 2 to about 7 molar equivalents per molar equivalent of the compound of formula (II). 
Postupak prema zahtjevu 1, naznačen time da je količina agensa za aciliranje u rasponu od oko 1 do oko 15, od oko 1 do oko 10 ili od oko 2 do oko 7 molarnih ekvivalenata po molarnom ekvivalentu spoja formule (II).
The mat of claim 1, wherein the base has different thicknesses at opposed outermost edges. 
Prenosivi podložak prema patentnom zahtjevu 1, naznačen time, da osnova ima različite debljine (T2, T3) na suprotnim krajnjim vanjskim rubovima.
The present invention therefore provides in a further aspect pharmaceutical compositions comprising a new compound of formula (I) and/or geometric isomers and/or stereoisomers and/or diastereomers and/or physiologically acceptable salts and/or hydrates and/or solvates thereof and physiologically acceptable carriers. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj formule (1) kao što je definiran u bilo kojem zahtjevu od 1 do 4 i/ili njegove geometrijske izomere i/ili stereoizomere i/ili dijastereomere i/ili njegove fiziološki prihvatljive soli i/ili njegove hidrate i/ili solvate i uz to fiziološki prihvatljive nosače.
Moreover, the process according to the invention can be varied in a preferred manner such that materials being different from wood are inserted or incorporated into the block of wood, which is obtained by the gluing of the pieces of wood. 
Osim toga, postupak koji je u skladu s ovim izumom može se mijenjati na prikladan način tako da se materijali koji su različiti od drva umetnu ili ugrade u blok od drva koji je dobiven lijepljenjem komada od drva.
A reagent kit for determining the efficacy of a mycobacterial vaccine, comprising (a) a reagent for restimulating immune cells previously stimulated by a mycobacterial vaccine comprising a recombinant nucleic acid molecule encoding a fusion polypeptide comprising (a) a domain capable of eliciting an immune response and (b) a phagolysosomal escape domain, and (b) a reagent for detecting a Th17 immune response to purified protein derivative antigens. 
11. Uporaba reagens kita u postupku prema bilo kojem od patentnih zahtjeva 1-10 za određivanje efikasnosti rekombinantnog mikobakterijskog živog cjepiva, koje sadrži (a) reagens za restimulaciju imunih stanica iz prethodno cijepljenog subjekta i (b) reagens za detekciju Th17 imunog odgovora.
A pharmaceutical composition comprising a compound of any one of claims 1 to 5 and one or more pharmaceutically acceptable excipients, diluents, or carriers. 
jednu ili više farmaceutski prihvatljivih pomoćnih tvari, razrjeđivača ili podloga; i terapijski djelotvornu količinu inzulina lispro.
the third stream compressed in the compressor is cooled in a heat exchanger (21) by exchanging heat with the first stream, without employing a reliquefaction apparatus using a separate refrigerant, the third stream cooled in the heat exchanger (21) is decompressed by decompressing means (22,52), and the third stream decompressed by the decompressing means is in a gas-liquid mixed state and is supplied to a gas-liquid separator (23). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se treću struju, ukapljenu u izmjenjivaču topline (21), dekomprimira elementom za dekomprimiranje (22). Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se treću struju, dekomprimiranu u plinsko-tekuće miješano stanje, vraća u spremnik za teret (11).
Crystalline Citric Acid Co-Crystal of Compound of Formula (I-X) 
Kokristal limunske kiseline spoja formule (I-X) (lej.
A process for the preparation of a maleate salt of 4-((4-fluoro-2-methyl-1 H -indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline in the crystalline form Form A, as claimed in any one of claims 1 to 4, which comprises: 
Postupak za pripravu maleatne soli 4-(4-fluoro-2-metil-1H-indol-5-il)oksi)-6-metoksi-7-(3-(pirolidin-1ilpropoksi)kinazolina u kristalnoj Formi A, kako je navedeno u bilo kojem od zahtjeva od 1 do 4, naznačen time, da obuhvaća:
The stabilized etanercept composition of claim 2 wherein the stabilizer is magnesium chloride and the formulation comprises 2 mM to 10 mM magnesium chloride; optionally up to 6 wt.% sucrose; 25 to 150 mM NaCl; 1 to 30 mM sodium phosphate; wherein the composition has a pH of 6.0 to 6.6. 
Stabilizirana kompozicija etanercepta prema patentnom zahtjevu 2 gdje je stabilizator magnezij klorid i formulacija sadrži 2 mM do 10 mM magnezij klorida; po mogućnosti do najviše 6 tež.% saharoze; 25 do 150 mM NaCl; 1 do 30 mM natrij fosfata; pri čemu kompozicija ima pH od 6.0 do 6.6.
(a') providing a solution of staurosporine in a first solvent; (b') seeding the solution with purified staurosporine in a second solvent; and 
pribavljanje otopine N-benzoil-staurosporina u otapalu; stavljanje u doticaj otopine s drugim otapalom za stvaranje taloga; i
Solid pharmaceutical preparation according to Claim 1 and/or 2, characterized in that the filler is a sugar alcohol such as sorbitol or mannitol dulcitol, xylitol or ribitol, preferably sorbitol or mannitol, particular preferably mannitol, a sugar such as glucose, fructose, mannose, lactose, saccharose or maltose, preferably lactose, saccharose or maltose, particular preferably lactose, a starch such as potato starch, rice starch, maize starch or pregelatinized starch, preferably maize starch or pregelatinized starch, particular preferably maize starch, a cellulose such as powdered cellulose or microcrystalline cellulose, preferably microcrystalline cellulose, or a mixture thereof. 
Kruti farmaceutski pripravak prema zahtjevu 1 i/ili 2, naznačen time da punilo je šećermi alkohol kao što je sorbitol ili manitol, dulcitol, ksilitol ili ribitol, poželjno sorbitol ili manitol, naročito poželjno manitol, šećer kao što je glukoza, fruktoza, manoza, laktoza, saharoza ili maltoza, poželjno laktoza, saharoza ili maltoza, naročito poželjno laktoza, škrob kao što je kukuruzni škrob, rižin škrob, kukuruzni škrob ili preželatinirani škrob, poželjno kukuruzni škrob ili preželatinirani škrob, naročito poželjno kukuruzni škrob, celuloza kao što je celuloza u prahu ili mikrokristalna celuloza, poželjno mikrokristalna celuloza, ili njihova smjesa.
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises the amino acid sequence of SEQ ID NO: 110, 111, 387, 112, or 394. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78.
A method of producing integration-defective vector particles, comprising transfecting a packaging cell line with an integration-defective retroviral vector transfer cassette lacking a functional PPT, wherein the packaging cell line provides proteins for the retroviral vector to be packaged. 
Postupak za proizvodnju čestica vektora manjkavog u integraciji, koji obuhvaća transfekciju stanične linije za pakiranje retrovirusnom vektorskom kazetom za prijenos manjkavom u integraciji kojoj nedostaje 3’-PPT, gdje stanična linija za pakiranje osigurava proteine za pakiranje retrovirusnog vektora.
As has already been explained in the general part of the description, the groove structures 4 are thus protected from the ingress of contaminants during mechanical machining. 
Kako što je već objašnjeno u općem dijelu opisa, brazdaste strukture 4 su time, dakle, zaštićene od ulaska onečišćenja tijekom mehaničke strojne obrade.
The invention further provides the use of the (S)-enantiomer, or a pharmaceutically acceptable solvate or prodrug thereof, as set forth above, preferably substantially free of the (R)-enantiomer, in the preparation of a medicament composition in the treatment of a disease or condition that is associated with the activity of a voltage-gated sodium channel. 
(S)-Enantiomer u skladu s patentnim zahtjevom 1, ili njegov farmaceutski prihvatljiv solvat, naznačen time što je namijenjen upotrebi u liječenju bolesti ili stanja kod sisavca inhibiranjem struje iona kroz naponski natrijski kanal kod sisavca.
The method of claim 18, wherein the crystalline form I of cortexolone-17a-propionate is formulated in a composition comprising form I of cortexolone-17a-propionate and at least one physiologically acceptable excipient. 
Farmaceutski pripravak koji sadrži korteksolon-17a-propionat u kristalnom obliku III u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je navedeni spoj u smjesi s najmanje jednom fiziološki prihvatljivom pomoćnom tvari.
Alkyl and alkoxy groups preferably have from 1 to 12 carbon atoms. 
Alkil i alkoksi grupe poželjno imaju od 1 do 12 atoma ugljika.
R11 is hydrogen, together with R9 a double bond or together with R9 an epoxy group -O-; 
R? je vodik, zajedno s R'' je dvostruka veza ili zajedno s R'' je epoksi skupina -O-;
A use or compound for use as defined above wherein the psychosis or psychotic episode arises from or is associated with schizophrenia. 
* - Uporabu spoja prema gore navedenim uporabama pri čemu su psihoza ili psihotična epizoda potaknuti ili su povezani sa šizofrenijom.
wherein the first chamber is for alternately receiving the a metered dose of the liquid from the injector inlet at said first pressure when the trigger is in the first position, and providing the metered dose of the liquid to the outlet at said second pressure when the trigger is in said second position; and wherein the pressure switch is set to actuate the pump when the first pressure is greater than the second pressure and/or corresponding to a condition when the first chamber is filled with liquid. 
(C) sklop za doziranje tekućine (46) za osiguranje odmjerene doze tekućine za drvo koji obuhvaća prvu komoru (50) koja je naizmjence u fluidnoj vezi s ulazom za ubrizgavanje i izlazom za ubrizgavanje; i drugu komoru (48) koja je kooperativno povezana s prvom komorom koja je prilagođena da sadrži plin pod drugim tlakom iznad tlaka okoline koji ima utjecaj na prvu komoru tako da se volumeni prve i druge komore mijenjaju obrnuto proporcionalno jedan prema drugom pri čemu je prva komora za naizmjenično primanje izmjerene doze tekućine iz ulaza za ubrizgavanje pri navedenom prvom tlaku kada je okidač u prvom položaju, te daje odmjerenu dozu tekućine u izlazni otvor pri navedenom drugom tlaku kada je okidač u navedenom drugom položaju; 1 pri čemu je tlačna sklopka podešena da aktivira pumpu kada je prvi tlak veći od drugog tlaka i/ili odgovara stanju kada je prva komora napunjena tekućinom.
The reactions described above are conveniently performed in the presence of a suitable base (such as those described above in process (a), for example potassium carbonate, triethylamine, 4-dimethylaminopyridine or di-isopropylethylamine) and conveniently in the presence of an inert solvent or diluent (for example the inert solvents and diluents described in process (a) such as N -methylpyrrolidin-2-one, acetonitrile, N, N -dimethylacetamide, methanol, ethanol or methylene chloride). 
Gore opisane reakcije prikladno se provode u prisutnosti odgovarajuće baze (poput onih navedenih za postupak (a), na primjer kalij-karbonat, trietilamin, 4-dimetilaminopiridin ili diizopropiletilamin) i prikladno u prisutnosti inertnog otapala ili razrjeđivača (poput inertnih otapala i razrjeđivača opisanih za postupak (a), poput N-metilpirolidin-2-ona, acetonitrila, N,N-dimetilacetamida, metanola, etanola ili metilen klorida).
For major clarity the description of the device according to the present invention continues with reference to the enclosed drawings, which are intended for purposes of illustration only and not in a limiting sense, whereby: FIG. 
Veća jasnoća opisa uređaja koji je u skladu s predmetnim izumom biti će dobivena u nastavku s pozivom na priložene crteže kojima je namjera samo prikazivanje ovog izuma, a ne njegovo ograničavanje, pri čemu slike pokazuju sljedeće:
If the drying is carried out in a flow of humid insert gas, the relative humidity of the gas should be adjusted so as not to dehydrate the MTC pentahydrate form A. In some embodiments, the relative humidity should not be below 30%. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se navedeno sušenje u protoku plina poželjno izvodi na temperaturi koja nije viša od 40*C te uz relativnu vlažnost plina koja nije ispod 30%.
PM01183, or a pharmaceutically acceptable salt thereof, for use in increasing the therapeutic efficacy of a mitotic inhibitor in the treatment of cancer, which comprises administering to a patient in need thereof a therapeutically effective amount of PM01183, or a pharmaceutically acceptable salt thereof, in synergistic combination with said mitotic inhibitor, wherein the mitotic inhibitor is selected from paclitaxel, docetaxel, vincristine and vinorelbine. 
PM01183, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u povećavanju terapijske djelotvornosti antimetabolita u liječenju raka, naznačen time što se upotreba sastoji u primjeni na pacijentu kojem je to potrebno terapijski djelotvorna količina PM01183, ili njegove farmaceutski prihvatljive soli, u sinergističkoj kombinaciji s navedenim antimetabolitom, gdje se antimetabolit bira između 5-fluoruracila, gemcitabina, citarabina, kapecitabina, decitabina, floksuridina, aminopterina, metotreksata, pemetrekseda i raltitrekseda.
and R2 together with the carbon atoms Ca and Cb to which they are attached form 
R' i R', zajedno s ugljikovim atomima C* i C* na koje su priključeni, tvore:
The present invention relates to a compound having the general formula I 
Ovaj izum se odnosi na spoj opće formule I di